Clinical Trial Highlights

• ROCKET-AF: Rivaroxaban Prevents Stroke as Effectively as Warfarin, with Lower Bleeding Risk
• DEFINE: CETP Inhibition with Anacetrapib Significantly Raises HDL Cholesterol and Further Lowers LDL
• Benefits of Inducing ApoA1 Synthesis Still Unclear: Results from ASSERT
• BASKET-PROVE: DES Just as Safe as BMS in Large Coronary Vessels
• ACT Trial Results Should Change Clinical Practice
• SMART-AV: No Benefit to Customized AV Delay in CRT
• Results from EMPHASIS-HF
• Results from Symplicity HTN-2
• High-Dose Clopidogrel in Patients with High Residual Reactivity: Results from the GRAVITAS Trial
• Results from the ASCEND-HF Trial
• No Reduction in Recurrent AF with Omega-3 Fatty Acids
• CLOSURE I: No Reduction in Recurrent Stroke or TIA with Septal Closure
• Results from the ASCOT Trial